nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A7—Estradiol—osteoporosis	0.0563	0.111	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.0563	0.111	CbGbCtD
Nefazodone—ABCB1—Ethinyl Estradiol—osteoporosis	0.0427	0.0841	CbGbCtD
Nefazodone—CYP3A5—Estradiol—osteoporosis	0.0422	0.0833	CbGbCtD
Nefazodone—CYP3A4—Estropipate—osteoporosis	0.0397	0.0782	CbGbCtD
Nefazodone—CYP3A4—Calcitriol—osteoporosis	0.0397	0.0782	CbGbCtD
Nefazodone—CYP2D6—Cholecalciferol—osteoporosis	0.0321	0.0634	CbGbCtD
Nefazodone—CYP3A4—Ergocalciferol—osteoporosis	0.0317	0.0625	CbGbCtD
Nefazodone—ABCB1—Conjugated Estrogens—osteoporosis	0.0313	0.0617	CbGbCtD
Nefazodone—ABCB1—Estradiol—osteoporosis	0.0275	0.0542	CbGbCtD
Nefazodone—CYP3A4—Raloxifene—osteoporosis	0.0265	0.0522	CbGbCtD
Nefazodone—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0256	0.0504	CbGbCtD
Nefazodone—CYP3A4—Cholecalciferol—osteoporosis	0.0204	0.0403	CbGbCtD
Nefazodone—CYP3A4—Conjugated Estrogens—osteoporosis	0.0188	0.037	CbGbCtD
Nefazodone—CYP3A4—Estradiol—osteoporosis	0.0165	0.0325	CbGbCtD
Nefazodone—Vertigo—Conjugated Estrogens—osteoporosis	0.000273	0.000635	CcSEcCtD
Nefazodone—Hyperhidrosis—Pamidronate—osteoporosis	0.000273	0.000634	CcSEcCtD
Nefazodone—Syncope—Conjugated Estrogens—osteoporosis	0.000273	0.000634	CcSEcCtD
Nefazodone—Hypertension—Zoledronate—osteoporosis	0.000273	0.000634	CcSEcCtD
Nefazodone—Hypersensitivity—Alendronate—osteoporosis	0.000272	0.000634	CcSEcCtD
Nefazodone—Headache—Etidronic acid—osteoporosis	0.000272	0.000632	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00027	0.000629	CcSEcCtD
Nefazodone—Asthenia—Estropipate—osteoporosis	0.000269	0.000627	CcSEcCtD
Nefazodone—Visual impairment—Estradiol—osteoporosis	0.000269	0.000626	CcSEcCtD
Nefazodone—Anorexia—Pamidronate—osteoporosis	0.000269	0.000625	CcSEcCtD
Nefazodone—Myalgia—Zoledronate—osteoporosis	0.000269	0.000625	CcSEcCtD
Nefazodone—Chest pain—Zoledronate—osteoporosis	0.000269	0.000625	CcSEcCtD
Nefazodone—Arthralgia—Zoledronate—osteoporosis	0.000269	0.000625	CcSEcCtD
Nefazodone—Palpitations—Conjugated Estrogens—osteoporosis	0.000269	0.000625	CcSEcCtD
Nefazodone—Insomnia—Risedronate—osteoporosis	0.000268	0.000624	CcSEcCtD
Nefazodone—Anxiety—Zoledronate—osteoporosis	0.000268	0.000623	CcSEcCtD
Nefazodone—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000267	0.000621	CcSEcCtD
Nefazodone—Paraesthesia—Risedronate—osteoporosis	0.000266	0.00062	CcSEcCtD
Nefazodone—Pruritus—Estropipate—osteoporosis	0.000266	0.000618	CcSEcCtD
Nefazodone—Discomfort—Zoledronate—osteoporosis	0.000266	0.000618	CcSEcCtD
Nefazodone—Asthenia—Alendronate—osteoporosis	0.000265	0.000617	CcSEcCtD
Nefazodone—Hypersensitivity—Ibandronate—osteoporosis	0.000265	0.000617	CcSEcCtD
Nefazodone—Cough—Conjugated Estrogens—osteoporosis	0.000265	0.000617	CcSEcCtD
Nefazodone—Dyspnoea—Risedronate—osteoporosis	0.000265	0.000615	CcSEcCtD
Nefazodone—Erythema multiforme—Estradiol—osteoporosis	0.000264	0.000615	CcSEcCtD
Nefazodone—Hypotension—Pamidronate—osteoporosis	0.000264	0.000613	CcSEcCtD
Nefazodone—Convulsion—Conjugated Estrogens—osteoporosis	0.000263	0.000613	CcSEcCtD
Nefazodone—Dry mouth—Zoledronate—osteoporosis	0.000263	0.000611	CcSEcCtD
Nefazodone—Pruritus—Alendronate—osteoporosis	0.000262	0.000609	CcSEcCtD
Nefazodone—Dyspepsia—Risedronate—osteoporosis	0.000261	0.000608	CcSEcCtD
Nefazodone—Tinnitus—Estradiol—osteoporosis	0.000261	0.000606	CcSEcCtD
Nefazodone—Constipation—Ethinyl Estradiol—osteoporosis	0.00026	0.000605	CcSEcCtD
Nefazodone—Confusional state—Zoledronate—osteoporosis	0.00026	0.000604	CcSEcCtD
Nefazodone—Hypersensitivity—Calcitriol—osteoporosis	0.00026	0.000604	CcSEcCtD
Nefazodone—Flushing—Estradiol—osteoporosis	0.000259	0.000603	CcSEcCtD
Nefazodone—Myalgia—Conjugated Estrogens—osteoporosis	0.000259	0.000602	CcSEcCtD
Nefazodone—Chest pain—Conjugated Estrogens—osteoporosis	0.000259	0.000602	CcSEcCtD
Nefazodone—Arthralgia—Conjugated Estrogens—osteoporosis	0.000259	0.000602	CcSEcCtD
Nefazodone—Asthenia—Ibandronate—osteoporosis	0.000258	0.000601	CcSEcCtD
Nefazodone—Anxiety—Conjugated Estrogens—osteoporosis	0.000258	0.0006	CcSEcCtD
Nefazodone—Nausea—Etidronic acid—osteoporosis	0.000258	0.0006	CcSEcCtD
Nefazodone—Anaphylactic shock—Zoledronate—osteoporosis	0.000258	0.000599	CcSEcCtD
Nefazodone—Oedema—Zoledronate—osteoporosis	0.000258	0.000599	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000257	0.000598	CcSEcCtD
Nefazodone—Diarrhoea—Estropipate—osteoporosis	0.000257	0.000598	CcSEcCtD
Nefazodone—Infection—Zoledronate—osteoporosis	0.000256	0.000595	CcSEcCtD
Nefazodone—Insomnia—Pamidronate—osteoporosis	0.000255	0.000593	CcSEcCtD
Nefazodone—Pruritus—Ibandronate—osteoporosis	0.000255	0.000593	CcSEcCtD
Nefazodone—Pain—Risedronate—osteoporosis	0.000254	0.00059	CcSEcCtD
Nefazodone—Constipation—Risedronate—osteoporosis	0.000254	0.00059	CcSEcCtD
Nefazodone—Shock—Zoledronate—osteoporosis	0.000253	0.00059	CcSEcCtD
Nefazodone—Paraesthesia—Pamidronate—osteoporosis	0.000253	0.000589	CcSEcCtD
Nefazodone—Diarrhoea—Alendronate—osteoporosis	0.000253	0.000589	CcSEcCtD
Nefazodone—Asthenia—Calcitriol—osteoporosis	0.000253	0.000588	CcSEcCtD
Nefazodone—Thrombocytopenia—Zoledronate—osteoporosis	0.000252	0.000587	CcSEcCtD
Nefazodone—Dyspnoea—Pamidronate—osteoporosis	0.000251	0.000585	CcSEcCtD
Nefazodone—Tachycardia—Zoledronate—osteoporosis	0.000251	0.000585	CcSEcCtD
Nefazodone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000251	0.000583	CcSEcCtD
Nefazodone—Chills—Estradiol—osteoporosis	0.000251	0.000583	CcSEcCtD
Nefazodone—Somnolence—Pamidronate—osteoporosis	0.000251	0.000583	CcSEcCtD
Nefazodone—Pruritus—Calcitriol—osteoporosis	0.000249	0.00058	CcSEcCtD
Nefazodone—Hyperhidrosis—Zoledronate—osteoporosis	0.000249	0.000579	CcSEcCtD
Nefazodone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000249	0.000579	CcSEcCtD
Nefazodone—Diarrhoea—Raloxifene—osteoporosis	0.000249	0.000579	CcSEcCtD
Nefazodone—Dyspepsia—Pamidronate—osteoporosis	0.000248	0.000578	CcSEcCtD
Nefazodone—Dizziness—Estropipate—osteoporosis	0.000248	0.000578	CcSEcCtD
Nefazodone—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000248	0.000577	CcSEcCtD
Nefazodone—Oedema—Conjugated Estrogens—osteoporosis	0.000248	0.000577	CcSEcCtD
Nefazodone—Alopecia—Estradiol—osteoporosis	0.000247	0.000574	CcSEcCtD
Nefazodone—Infection—Conjugated Estrogens—osteoporosis	0.000246	0.000573	CcSEcCtD
Nefazodone—Diarrhoea—Ibandronate—osteoporosis	0.000246	0.000573	CcSEcCtD
Nefazodone—Anorexia—Zoledronate—osteoporosis	0.000246	0.000571	CcSEcCtD
Nefazodone—Decreased appetite—Pamidronate—osteoporosis	0.000245	0.00057	CcSEcCtD
Nefazodone—Dizziness—Alendronate—osteoporosis	0.000245	0.000569	CcSEcCtD
Nefazodone—Shock—Conjugated Estrogens—osteoporosis	0.000244	0.000568	CcSEcCtD
Nefazodone—Gastrointestinal pain—Risedronate—osteoporosis	0.000243	0.000564	CcSEcCtD
Nefazodone—Tachycardia—Conjugated Estrogens—osteoporosis	0.000242	0.000563	CcSEcCtD
Nefazodone—Urticaria—Ethinyl Estradiol—osteoporosis	0.000242	0.000562	CcSEcCtD
Nefazodone—Pain—Pamidronate—osteoporosis	0.000241	0.000561	CcSEcCtD
Nefazodone—Constipation—Pamidronate—osteoporosis	0.000241	0.000561	CcSEcCtD
Nefazodone—Diarrhoea—Calcitriol—osteoporosis	0.000241	0.000561	CcSEcCtD
Nefazodone—Hypotension—Zoledronate—osteoporosis	0.000241	0.00056	CcSEcCtD
Nefazodone—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000241	0.00056	CcSEcCtD
Nefazodone—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000241	0.00056	CcSEcCtD
Nefazodone—Dizziness—Raloxifene—osteoporosis	0.00024	0.000559	CcSEcCtD
Nefazodone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00024	0.000558	CcSEcCtD
Nefazodone—Flatulence—Estradiol—osteoporosis	0.00024	0.000558	CcSEcCtD
Nefazodone—Vomiting—Estropipate—osteoporosis	0.000239	0.000555	CcSEcCtD
Nefazodone—Dysgeusia—Estradiol—osteoporosis	0.000238	0.000554	CcSEcCtD
Nefazodone—Dizziness—Ibandronate—osteoporosis	0.000238	0.000554	CcSEcCtD
Nefazodone—Rash—Estropipate—osteoporosis	0.000237	0.000551	CcSEcCtD
Nefazodone—Dermatitis—Estropipate—osteoporosis	0.000237	0.00055	CcSEcCtD
Nefazodone—Anorexia—Conjugated Estrogens—osteoporosis	0.000236	0.00055	CcSEcCtD
Nefazodone—Urticaria—Risedronate—osteoporosis	0.000236	0.000548	CcSEcCtD
Nefazodone—Back pain—Estradiol—osteoporosis	0.000235	0.000547	CcSEcCtD
Nefazodone—Headache—Estropipate—osteoporosis	0.000235	0.000547	CcSEcCtD
Nefazodone—Vomiting—Alendronate—osteoporosis	0.000235	0.000547	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000235	0.000546	CcSEcCtD
Nefazodone—Abdominal pain—Risedronate—osteoporosis	0.000235	0.000546	CcSEcCtD
Nefazodone—Body temperature increased—Risedronate—osteoporosis	0.000235	0.000546	CcSEcCtD
Nefazodone—Muscle spasms—Estradiol—osteoporosis	0.000234	0.000544	CcSEcCtD
Nefazodone—Rash—Alendronate—osteoporosis	0.000233	0.000542	CcSEcCtD
Nefazodone—Insomnia—Zoledronate—osteoporosis	0.000233	0.000542	CcSEcCtD
Nefazodone—Dermatitis—Alendronate—osteoporosis	0.000233	0.000542	CcSEcCtD
Nefazodone—Feeling abnormal—Pamidronate—osteoporosis	0.000232	0.000541	CcSEcCtD
Nefazodone—Hypotension—Conjugated Estrogens—osteoporosis	0.000232	0.000539	CcSEcCtD
Nefazodone—Headache—Alendronate—osteoporosis	0.000232	0.000539	CcSEcCtD
Nefazodone—Paraesthesia—Zoledronate—osteoporosis	0.000231	0.000538	CcSEcCtD
Nefazodone—Vomiting—Raloxifene—osteoporosis	0.000231	0.000538	CcSEcCtD
Nefazodone—Gastrointestinal pain—Pamidronate—osteoporosis	0.000231	0.000537	CcSEcCtD
Nefazodone—Dyspnoea—Zoledronate—osteoporosis	0.00023	0.000534	CcSEcCtD
Nefazodone—Rash—Raloxifene—osteoporosis	0.000229	0.000533	CcSEcCtD
Nefazodone—Dermatitis—Raloxifene—osteoporosis	0.000229	0.000533	CcSEcCtD
Nefazodone—Somnolence—Zoledronate—osteoporosis	0.000229	0.000533	CcSEcCtD
Nefazodone—Vomiting—Ibandronate—osteoporosis	0.000229	0.000533	CcSEcCtD
Nefazodone—Tremor—Estradiol—osteoporosis	0.000228	0.00053	CcSEcCtD
Nefazodone—Headache—Raloxifene—osteoporosis	0.000228	0.00053	CcSEcCtD
Nefazodone—Rash—Ibandronate—osteoporosis	0.000227	0.000528	CcSEcCtD
Nefazodone—Dermatitis—Ibandronate—osteoporosis	0.000227	0.000528	CcSEcCtD
Nefazodone—Dyspepsia—Zoledronate—osteoporosis	0.000227	0.000528	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000226	0.000526	CcSEcCtD
Nefazodone—Ill-defined disorder—Estradiol—osteoporosis	0.000226	0.000525	CcSEcCtD
Nefazodone—Headache—Ibandronate—osteoporosis	0.000226	0.000525	CcSEcCtD
Nefazodone—Insomnia—Conjugated Estrogens—osteoporosis	0.000224	0.000522	CcSEcCtD
Nefazodone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000224	0.000522	CcSEcCtD
Nefazodone—Vomiting—Calcitriol—osteoporosis	0.000224	0.000521	CcSEcCtD
Nefazodone—Decreased appetite—Zoledronate—osteoporosis	0.000224	0.000521	CcSEcCtD
Nefazodone—Agitation—Estradiol—osteoporosis	0.000224	0.00052	CcSEcCtD
Nefazodone—Nausea—Estropipate—osteoporosis	0.000223	0.000519	CcSEcCtD
Nefazodone—Abdominal pain—Pamidronate—osteoporosis	0.000223	0.000519	CcSEcCtD
Nefazodone—Body temperature increased—Pamidronate—osteoporosis	0.000223	0.000519	CcSEcCtD
Nefazodone—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000223	0.000518	CcSEcCtD
Nefazodone—Angioedema—Estradiol—osteoporosis	0.000222	0.000517	CcSEcCtD
Nefazodone—Rash—Calcitriol—osteoporosis	0.000222	0.000517	CcSEcCtD
Nefazodone—Dermatitis—Calcitriol—osteoporosis	0.000222	0.000516	CcSEcCtD
Nefazodone—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000221	0.000515	CcSEcCtD
Nefazodone—Headache—Calcitriol—osteoporosis	0.000221	0.000514	CcSEcCtD
Nefazodone—Somnolence—Conjugated Estrogens—osteoporosis	0.000221	0.000513	CcSEcCtD
Nefazodone—Pain—Zoledronate—osteoporosis	0.00022	0.000513	CcSEcCtD
Nefazodone—Constipation—Zoledronate—osteoporosis	0.00022	0.000513	CcSEcCtD
Nefazodone—Nausea—Alendronate—osteoporosis	0.00022	0.000511	CcSEcCtD
Nefazodone—Malaise—Estradiol—osteoporosis	0.000219	0.00051	CcSEcCtD
Nefazodone—Hypersensitivity—Risedronate—osteoporosis	0.000219	0.000509	CcSEcCtD
Nefazodone—Vertigo—Estradiol—osteoporosis	0.000219	0.000508	CcSEcCtD
Nefazodone—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000218	0.000508	CcSEcCtD
Nefazodone—Asthenia—Ethinyl Estradiol—osteoporosis	0.000218	0.000508	CcSEcCtD
Nefazodone—Syncope—Estradiol—osteoporosis	0.000218	0.000508	CcSEcCtD
Nefazodone—Nausea—Raloxifene—osteoporosis	0.000216	0.000503	CcSEcCtD
Nefazodone—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000216	0.000502	CcSEcCtD
Nefazodone—Pruritus—Ethinyl Estradiol—osteoporosis	0.000215	0.000501	CcSEcCtD
Nefazodone—Palpitations—Estradiol—osteoporosis	0.000215	0.0005	CcSEcCtD
Nefazodone—Nausea—Ibandronate—osteoporosis	0.000214	0.000497	CcSEcCtD
Nefazodone—Loss of consciousness—Estradiol—osteoporosis	0.000214	0.000497	CcSEcCtD
Nefazodone—Asthenia—Risedronate—osteoporosis	0.000213	0.000495	CcSEcCtD
Nefazodone—Feeling abnormal—Zoledronate—osteoporosis	0.000212	0.000494	CcSEcCtD
Nefazodone—Cough—Estradiol—osteoporosis	0.000212	0.000494	CcSEcCtD
Nefazodone—Pain—Conjugated Estrogens—osteoporosis	0.000212	0.000493	CcSEcCtD
Nefazodone—Constipation—Conjugated Estrogens—osteoporosis	0.000212	0.000493	CcSEcCtD
Nefazodone—Gastrointestinal pain—Zoledronate—osteoporosis	0.000211	0.00049	CcSEcCtD
Nefazodone—Hypertension—Estradiol—osteoporosis	0.00021	0.000489	CcSEcCtD
Nefazodone—Pruritus—Risedronate—osteoporosis	0.00021	0.000488	CcSEcCtD
Nefazodone—Nausea—Calcitriol—osteoporosis	0.000209	0.000487	CcSEcCtD
Nefazodone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000208	0.000484	CcSEcCtD
Nefazodone—Hypersensitivity—Pamidronate—osteoporosis	0.000208	0.000483	CcSEcCtD
Nefazodone—Chest pain—Estradiol—osteoporosis	0.000207	0.000482	CcSEcCtD
Nefazodone—Arthralgia—Estradiol—osteoporosis	0.000207	0.000482	CcSEcCtD
Nefazodone—Myalgia—Estradiol—osteoporosis	0.000207	0.000482	CcSEcCtD
Nefazodone—Anxiety—Estradiol—osteoporosis	0.000206	0.00048	CcSEcCtD
Nefazodone—Urticaria—Zoledronate—osteoporosis	0.000205	0.000476	CcSEcCtD
Nefazodone—Discomfort—Estradiol—osteoporosis	0.000205	0.000476	CcSEcCtD
Nefazodone—Body temperature increased—Zoledronate—osteoporosis	0.000204	0.000474	CcSEcCtD
Nefazodone—Abdominal pain—Zoledronate—osteoporosis	0.000204	0.000474	CcSEcCtD
Nefazodone—Diarrhoea—Risedronate—osteoporosis	0.000203	0.000472	CcSEcCtD
Nefazodone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000203	0.000472	CcSEcCtD
Nefazodone—Dry mouth—Estradiol—osteoporosis	0.000203	0.000471	CcSEcCtD
Nefazodone—Asthenia—Pamidronate—osteoporosis	0.000202	0.000471	CcSEcCtD
Nefazodone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000201	0.000468	CcSEcCtD
Nefazodone—Confusional state—Estradiol—osteoporosis	0.0002	0.000466	CcSEcCtD
Nefazodone—Pruritus—Pamidronate—osteoporosis	0.0002	0.000464	CcSEcCtD
Nefazodone—Oedema—Estradiol—osteoporosis	0.000199	0.000462	CcSEcCtD
Nefazodone—Anaphylactic shock—Estradiol—osteoporosis	0.000199	0.000462	CcSEcCtD
Nefazodone—Infection—Estradiol—osteoporosis	0.000197	0.000459	CcSEcCtD
Nefazodone—Urticaria—Conjugated Estrogens—osteoporosis	0.000197	0.000458	CcSEcCtD
Nefazodone—Dizziness—Risedronate—osteoporosis	0.000196	0.000456	CcSEcCtD
Nefazodone—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000196	0.000456	CcSEcCtD
Nefazodone—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000196	0.000456	CcSEcCtD
Nefazodone—Shock—Estradiol—osteoporosis	0.000195	0.000454	CcSEcCtD
Nefazodone—Tachycardia—Estradiol—osteoporosis	0.000194	0.000451	CcSEcCtD
Nefazodone—Vomiting—Ethinyl Estradiol—osteoporosis	0.000193	0.00045	CcSEcCtD
Nefazodone—Diarrhoea—Pamidronate—osteoporosis	0.000193	0.000449	CcSEcCtD
Nefazodone—Hyperhidrosis—Estradiol—osteoporosis	0.000192	0.000447	CcSEcCtD
Nefazodone—Rash—Ethinyl Estradiol—osteoporosis	0.000192	0.000446	CcSEcCtD
Nefazodone—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000192	0.000446	CcSEcCtD
Nefazodone—Headache—Ethinyl Estradiol—osteoporosis	0.000191	0.000443	CcSEcCtD
Nefazodone—Hypersensitivity—Zoledronate—osteoporosis	0.00019	0.000442	CcSEcCtD
Nefazodone—Vomiting—Risedronate—osteoporosis	0.000189	0.000439	CcSEcCtD
Nefazodone—Rash—Risedronate—osteoporosis	0.000187	0.000435	CcSEcCtD
Nefazodone—Dermatitis—Risedronate—osteoporosis	0.000187	0.000435	CcSEcCtD
Nefazodone—Dizziness—Pamidronate—osteoporosis	0.000187	0.000434	CcSEcCtD
Nefazodone—Headache—Risedronate—osteoporosis	0.000186	0.000432	CcSEcCtD
Nefazodone—Asthenia—Zoledronate—osteoporosis	0.000185	0.00043	CcSEcCtD
Nefazodone—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000183	0.000425	CcSEcCtD
Nefazodone—Pruritus—Zoledronate—osteoporosis	0.000182	0.000424	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000181	0.000421	CcSEcCtD
Nefazodone—Nausea—Ethinyl Estradiol—osteoporosis	0.000181	0.00042	CcSEcCtD
Nefazodone—Insomnia—Estradiol—osteoporosis	0.00018	0.000418	CcSEcCtD
Nefazodone—Vomiting—Pamidronate—osteoporosis	0.000179	0.000417	CcSEcCtD
Nefazodone—Paraesthesia—Estradiol—osteoporosis	0.000178	0.000415	CcSEcCtD
Nefazodone—Asthenia—Conjugated Estrogens—osteoporosis	0.000178	0.000414	CcSEcCtD
Nefazodone—Rash—Pamidronate—osteoporosis	0.000178	0.000414	CcSEcCtD
Nefazodone—Dermatitis—Pamidronate—osteoporosis	0.000178	0.000413	CcSEcCtD
Nefazodone—Dyspnoea—Estradiol—osteoporosis	0.000177	0.000412	CcSEcCtD
Nefazodone—Headache—Pamidronate—osteoporosis	0.000177	0.000411	CcSEcCtD
Nefazodone—Somnolence—Estradiol—osteoporosis	0.000177	0.000411	CcSEcCtD
Nefazodone—Diarrhoea—Zoledronate—osteoporosis	0.000176	0.00041	CcSEcCtD
Nefazodone—Nausea—Risedronate—osteoporosis	0.000176	0.00041	CcSEcCtD
Nefazodone—Pruritus—Conjugated Estrogens—osteoporosis	0.000176	0.000408	CcSEcCtD
Nefazodone—Dyspepsia—Estradiol—osteoporosis	0.000175	0.000407	CcSEcCtD
Nefazodone—Decreased appetite—Estradiol—osteoporosis	0.000173	0.000401	CcSEcCtD
Nefazodone—Dizziness—Zoledronate—osteoporosis	0.00017	0.000396	CcSEcCtD
Nefazodone—Constipation—Estradiol—osteoporosis	0.00017	0.000395	CcSEcCtD
Nefazodone—Pain—Estradiol—osteoporosis	0.00017	0.000395	CcSEcCtD
Nefazodone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00017	0.000395	CcSEcCtD
Nefazodone—Nausea—Pamidronate—osteoporosis	0.000168	0.00039	CcSEcCtD
Nefazodone—Dizziness—Conjugated Estrogens—osteoporosis	0.000164	0.000382	CcSEcCtD
Nefazodone—Vomiting—Zoledronate—osteoporosis	0.000164	0.000381	CcSEcCtD
Nefazodone—Feeling abnormal—Estradiol—osteoporosis	0.000164	0.000381	CcSEcCtD
Nefazodone—Rash—Zoledronate—osteoporosis	0.000162	0.000378	CcSEcCtD
Nefazodone—Gastrointestinal pain—Estradiol—osteoporosis	0.000162	0.000378	CcSEcCtD
Nefazodone—Dermatitis—Zoledronate—osteoporosis	0.000162	0.000378	CcSEcCtD
Nefazodone—Headache—Zoledronate—osteoporosis	0.000161	0.000375	CcSEcCtD
Nefazodone—Vomiting—Conjugated Estrogens—osteoporosis	0.000158	0.000367	CcSEcCtD
Nefazodone—Urticaria—Estradiol—osteoporosis	0.000158	0.000367	CcSEcCtD
Nefazodone—Abdominal pain—Estradiol—osteoporosis	0.000157	0.000365	CcSEcCtD
Nefazodone—Body temperature increased—Estradiol—osteoporosis	0.000157	0.000365	CcSEcCtD
Nefazodone—Rash—Conjugated Estrogens—osteoporosis	0.000156	0.000364	CcSEcCtD
Nefazodone—Dermatitis—Conjugated Estrogens—osteoporosis	0.000156	0.000364	CcSEcCtD
Nefazodone—Headache—Conjugated Estrogens—osteoporosis	0.000155	0.000362	CcSEcCtD
Nefazodone—Nausea—Zoledronate—osteoporosis	0.000153	0.000356	CcSEcCtD
Nefazodone—Nausea—Conjugated Estrogens—osteoporosis	0.000147	0.000343	CcSEcCtD
Nefazodone—Hypersensitivity—Estradiol—osteoporosis	0.000146	0.00034	CcSEcCtD
Nefazodone—Asthenia—Estradiol—osteoporosis	0.000142	0.000331	CcSEcCtD
Nefazodone—Pruritus—Estradiol—osteoporosis	0.00014	0.000327	CcSEcCtD
Nefazodone—Diarrhoea—Estradiol—osteoporosis	0.000136	0.000316	CcSEcCtD
Nefazodone—Dizziness—Estradiol—osteoporosis	0.000131	0.000305	CcSEcCtD
Nefazodone—Vomiting—Estradiol—osteoporosis	0.000126	0.000294	CcSEcCtD
Nefazodone—Rash—Estradiol—osteoporosis	0.000125	0.000291	CcSEcCtD
Nefazodone—Dermatitis—Estradiol—osteoporosis	0.000125	0.000291	CcSEcCtD
Nefazodone—Headache—Estradiol—osteoporosis	0.000124	0.000289	CcSEcCtD
Nefazodone—Nausea—Estradiol—osteoporosis	0.000118	0.000274	CcSEcCtD
Nefazodone—HTR2A—Signaling Pathways—RAP1A—osteoporosis	2.53e-05	0.000402	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGA—osteoporosis	2.53e-05	0.000402	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—RAP1A—osteoporosis	2.52e-05	0.000401	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTH—osteoporosis	2.52e-05	0.0004	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PKM—osteoporosis	2.51e-05	0.000399	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FDPS—osteoporosis	2.51e-05	0.000399	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CNR2—osteoporosis	2.51e-05	0.000398	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.5e-05	0.000397	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—ADCY5—osteoporosis	2.49e-05	0.000396	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—IDH2—osteoporosis	2.49e-05	0.000396	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—ADCY5—osteoporosis	2.49e-05	0.000396	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAP1A—osteoporosis	2.48e-05	0.000393	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTHLH—osteoporosis	2.47e-05	0.000392	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BMP2—osteoporosis	2.47e-05	0.000392	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFATC1—osteoporosis	2.47e-05	0.000392	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CNR2—osteoporosis	2.46e-05	0.00039	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTHLH—osteoporosis	2.46e-05	0.00039	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BMP2—osteoporosis	2.46e-05	0.00039	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—DKK1—osteoporosis	2.45e-05	0.000389	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.45e-05	0.000388	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—ADCY5—osteoporosis	2.44e-05	0.000387	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFATC1—osteoporosis	2.42e-05	0.000384	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—FGB—osteoporosis	2.42e-05	0.000384	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—P4HB—osteoporosis	2.41e-05	0.000382	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—FGB—osteoporosis	2.4e-05	0.000382	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—DKK1—osteoporosis	2.4e-05	0.000381	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPD2—osteoporosis	2.38e-05	0.000378	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PGLS—osteoporosis	2.38e-05	0.000378	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—WNT1—osteoporosis	2.36e-05	0.000375	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTHLH—osteoporosis	2.35e-05	0.000373	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BMP2—osteoporosis	2.35e-05	0.000373	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—IDH2—osteoporosis	2.35e-05	0.000373	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTH—osteoporosis	2.34e-05	0.000372	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP27A1—osteoporosis	2.34e-05	0.000372	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PSMA2—osteoporosis	2.33e-05	0.000371	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PSMA5—osteoporosis	2.33e-05	0.000371	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PSMA5—osteoporosis	2.32e-05	0.000369	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PSMA2—osteoporosis	2.32e-05	0.000369	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—WNT1—osteoporosis	2.31e-05	0.000367	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	2.3e-05	0.000366	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FGB—osteoporosis	2.3e-05	0.000366	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.3e-05	0.000365	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGA—osteoporosis	2.29e-05	0.000364	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.29e-05	0.000364	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CNR2—osteoporosis	2.28e-05	0.000363	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ACP5—osteoporosis	2.28e-05	0.000362	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	2.27e-05	0.00036	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—ADCY5—osteoporosis	2.26e-05	0.000359	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP19A1—osteoporosis	2.26e-05	0.000358	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGA—osteoporosis	2.25e-05	0.000357	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	2.25e-05	0.000357	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—DKK1—osteoporosis	2.23e-05	0.000354	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ENO1—osteoporosis	2.23e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PSMA5—osteoporosis	2.22e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PSMA2—osteoporosis	2.22e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—ADCY5—osteoporosis	2.21e-05	0.000352	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP27A1—osteoporosis	2.21e-05	0.00035	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PSMA2—osteoporosis	2.19e-05	0.000348	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PSMA5—osteoporosis	2.19e-05	0.000348	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ATIC—osteoporosis	2.18e-05	0.000346	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PNP—osteoporosis	2.18e-05	0.000346	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CALCA—osteoporosis	2.17e-05	0.000345	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CALCA—osteoporosis	2.16e-05	0.000344	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ACP5—osteoporosis	2.15e-05	0.000341	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—WNT1—osteoporosis	2.15e-05	0.000341	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.15e-05	0.000341	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.14e-05	0.00034	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTHLH—osteoporosis	2.13e-05	0.000339	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BMP2—osteoporosis	2.13e-05	0.000339	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—POMC—osteoporosis	2.12e-05	0.000337	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TPI1—osteoporosis	2.12e-05	0.000336	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—POMC—osteoporosis	2.11e-05	0.000335	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTHLH—osteoporosis	2.09e-05	0.000332	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BMP2—osteoporosis	2.09e-05	0.000332	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGB—osteoporosis	2.09e-05	0.000332	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGA—osteoporosis	2.09e-05	0.000332	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CALCA—osteoporosis	2.07e-05	0.000329	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	2.06e-05	0.000327	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGB—osteoporosis	2.04e-05	0.000325	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ENO1—osteoporosis	2.04e-05	0.000324	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—POMC—osteoporosis	2.02e-05	0.000321	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PSMA2—osteoporosis	2.02e-05	0.00032	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PSMA5—osteoporosis	2.02e-05	0.00032	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PSMA2—osteoporosis	2.01e-05	0.000319	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PSMA5—osteoporosis	2.01e-05	0.000319	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPI1—osteoporosis	2e-05	0.000317	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—P4HB—osteoporosis	1.99e-05	0.000316	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KL—osteoporosis	1.97e-05	0.000314	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	1.97e-05	0.000313	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	1.97e-05	0.000313	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KL—osteoporosis	1.96e-05	0.000312	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GAPDH—osteoporosis	1.95e-05	0.00031	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	1.94e-05	0.000308	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BMP2—osteoporosis	1.94e-05	0.000308	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—POMC—osteoporosis	1.93e-05	0.000306	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—POMC—osteoporosis	1.92e-05	0.000304	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—RAP1A—osteoporosis	1.9e-05	0.000302	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGB—osteoporosis	1.9e-05	0.000302	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KL—osteoporosis	1.88e-05	0.000299	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6R—osteoporosis	1.88e-05	0.000298	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CALCA—osteoporosis	1.88e-05	0.000298	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—P4HB—osteoporosis	1.88e-05	0.000298	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6R—osteoporosis	1.87e-05	0.000297	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—OXCT1—osteoporosis	1.85e-05	0.000294	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CA2—osteoporosis	1.85e-05	0.000294	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ADCY5—osteoporosis	1.84e-05	0.000293	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GAPDH—osteoporosis	1.84e-05	0.000293	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CALCA—osteoporosis	1.84e-05	0.000292	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GPX1—osteoporosis	1.84e-05	0.000292	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—POMC—osteoporosis	1.83e-05	0.000291	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.83e-05	0.000291	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.83e-05	0.000291	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—POMC—osteoporosis	1.83e-05	0.000291	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MGLL—osteoporosis	1.8e-05	0.000287	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—RAP1A—osteoporosis	1.79e-05	0.000285	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	1.79e-05	0.000285	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6R—osteoporosis	1.79e-05	0.000284	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP19A1—osteoporosis	1.78e-05	0.000283	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CALCA—osteoporosis	1.71e-05	0.000271	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KL—osteoporosis	1.71e-05	0.000271	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—MTHFR—osteoporosis	1.69e-05	0.000269	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KL—osteoporosis	1.67e-05	0.000265	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	1.67e-05	0.000265	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—POMC—osteoporosis	1.66e-05	0.000264	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP19A1—osteoporosis	1.63e-05	0.000259	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—POMC—osteoporosis	1.63e-05	0.000259	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6R—osteoporosis	1.62e-05	0.000258	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	1.59e-05	0.000252	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KL—osteoporosis	1.55e-05	0.000246	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADCY5—osteoporosis	1.55e-05	0.000246	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ENO1—osteoporosis	1.54e-05	0.000244	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADCY5—osteoporosis	1.54e-05	0.000244	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—IDH2—osteoporosis	1.53e-05	0.000244	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TGFB1—osteoporosis	1.52e-05	0.000242	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PSMA5—osteoporosis	1.52e-05	0.000241	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PSMA2—osteoporosis	1.52e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—POMC—osteoporosis	1.51e-05	0.00024	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SPP1—osteoporosis	1.5e-05	0.000238	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SPP1—osteoporosis	1.49e-05	0.000236	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	1.48e-05	0.000234	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADCY5—osteoporosis	1.47e-05	0.000234	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ADCY5—osteoporosis	1.45e-05	0.000231	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ENO1—osteoporosis	1.45e-05	0.00023	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GPX1—osteoporosis	1.45e-05	0.00023	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.44e-05	0.000229	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PSMA2—osteoporosis	1.43e-05	0.000227	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PSMA5—osteoporosis	1.43e-05	0.000227	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SPP1—osteoporosis	1.42e-05	0.000226	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ACP5—osteoporosis	1.4e-05	0.000223	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—POMC—osteoporosis	1.36e-05	0.000215	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IRS2—osteoporosis	1.35e-05	0.000215	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IRS2—osteoporosis	1.35e-05	0.000214	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MTHFR—osteoporosis	1.34e-05	0.000212	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADCY5—osteoporosis	1.34e-05	0.000212	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ADCY5—osteoporosis	1.33e-05	0.000212	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GPX1—osteoporosis	1.33e-05	0.000211	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—LEP—osteoporosis	1.32e-05	0.00021	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—LEP—osteoporosis	1.32e-05	0.000209	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	1.31e-05	0.000208	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPI1—osteoporosis	1.3e-05	0.000207	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SPP1—osteoporosis	1.29e-05	0.000205	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IRS2—osteoporosis	1.29e-05	0.000205	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SPP1—osteoporosis	1.27e-05	0.000201	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ESR1—osteoporosis	1.26e-05	0.000201	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—LEP—osteoporosis	1.26e-05	0.0002	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ESR1—osteoporosis	1.26e-05	0.0002	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP19A1—osteoporosis	1.23e-05	0.000195	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—P4HB—osteoporosis	1.23e-05	0.000195	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTHFR—osteoporosis	1.23e-05	0.000195	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	1.22e-05	0.000193	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GAPDH—osteoporosis	1.2e-05	0.000191	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ESR1—osteoporosis	1.2e-05	0.000191	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IRS1—osteoporosis	1.18e-05	0.000188	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SPP1—osteoporosis	1.18e-05	0.000187	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IRS1—osteoporosis	1.18e-05	0.000187	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RAP1A—osteoporosis	1.17e-05	0.000186	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IRS2—osteoporosis	1.17e-05	0.000186	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.16e-05	0.000184	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IRS2—osteoporosis	1.14e-05	0.000182	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LEP—osteoporosis	1.14e-05	0.000182	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—POMC—osteoporosis	1.14e-05	0.000181	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—POMC—osteoporosis	1.13e-05	0.00018	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IRS1—osteoporosis	1.12e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—osteoporosis	1.12e-05	0.000178	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6R—osteoporosis	1.11e-05	0.000176	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6R—osteoporosis	1.1e-05	0.000175	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—osteoporosis	1.09e-05	0.000174	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ESR1—osteoporosis	1.09e-05	0.000173	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—osteoporosis	1.09e-05	0.000173	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—POMC—osteoporosis	1.08e-05	0.000172	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ESR1—osteoporosis	1.07e-05	0.00017	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—POMC—osteoporosis	1.07e-05	0.00017	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IRS2—osteoporosis	1.06e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6R—osteoporosis	1.06e-05	0.000168	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—osteoporosis	1.04e-05	0.000165	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—osteoporosis	1.04e-05	0.000165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IRS1—osteoporosis	1.02e-05	0.000162	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ADCY5—osteoporosis	1.01e-05	0.00016	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—osteoporosis	1e-05	0.000159	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IRS1—osteoporosis	9.99e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—osteoporosis	9.94e-06	0.000158	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—osteoporosis	9.83e-06	0.000156	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—osteoporosis	9.8e-06	0.000156	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—osteoporosis	9.62e-06	0.000153	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6R—osteoporosis	9.59e-06	0.000152	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO1—osteoporosis	9.48e-06	0.000151	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ADCY5—osteoporosis	9.47e-06	0.00015	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—osteoporosis	9.45e-06	0.00015	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—osteoporosis	9.44e-06	0.00015	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6R—osteoporosis	9.39e-06	0.000149	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMA5—osteoporosis	9.34e-06	0.000148	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMA2—osteoporosis	9.34e-06	0.000148	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IRS1—osteoporosis	9.28e-06	0.000147	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—osteoporosis	9.26e-06	0.000147	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—osteoporosis	9.24e-06	0.000147	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—osteoporosis	8.94e-06	0.000142	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6R—osteoporosis	8.72e-06	0.000139	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—osteoporosis	8.71e-06	0.000138	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—osteoporosis	8.6e-06	0.000137	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—osteoporosis	8.37e-06	0.000133	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—osteoporosis	8.32e-06	0.000132	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—osteoporosis	7.97e-06	0.000127	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP19A1—osteoporosis	7.58e-06	0.00012	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—osteoporosis	7.39e-06	0.000117	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—osteoporosis	7.23e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—osteoporosis	7.08e-06	0.000112	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—osteoporosis	6.97e-06	0.000111	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—osteoporosis	6.58e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—osteoporosis	6.58e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—osteoporosis	6.56e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—osteoporosis	6.54e-06	0.000104	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—osteoporosis	6.53e-06	0.000104	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—osteoporosis	6.26e-06	9.95e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—osteoporosis	6.25e-06	9.92e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADCY5—osteoporosis	6.19e-06	9.84e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—osteoporosis	6.17e-06	9.8e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—osteoporosis	5.7e-06	9.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—osteoporosis	5.68e-06	9.02e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—osteoporosis	5.67e-06	9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—osteoporosis	5.56e-06	8.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	5.55e-06	8.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—osteoporosis	5.17e-06	8.21e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	5.16e-06	8.19e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—osteoporosis	4.94e-06	7.85e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—osteoporosis	4.92e-06	7.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—osteoporosis	4.71e-06	7.48e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—osteoporosis	4.55e-06	7.23e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—osteoporosis	4.27e-06	6.78e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—osteoporosis	4.18e-06	6.64e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—osteoporosis	3.88e-06	6.17e-05	CbGpPWpGaD
